United Therapeutics Corporation’s UTHR revealed though an 8-K filing that it was informed (Mar 15, 2016) by its partner Medtronic plc MDT that the FDA had issued a response letter to Medtronic’s ...

DUBLIN - July 31, 2018 - Medtronic plc (MDT) has received U.S. Food and Drug Administration (FDA) approval for the Implantable System for Remodulin® (ISR) to treat patients with pulmonary arterial ...

Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years. Remunity ® Pump for Remodulin ® (treprostinil; ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...

United Therapeutics Corporation UTHR shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for ...

Patients with pulmonary arterial hypertension will shortly have a more convenient way to treat their disease. United Therapeutics and DEKA Research & Development have received the Food and Drug ...

The FDA has cleared the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also known as the RemUnity system. The Food and Drug Administration (FDA) has cleared the Unity ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...